Cargando…

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

Antibody-based therapeutics targeting the inhibitory receptors PD-1, PD-L1, or CTLA-4 have shown remarkable clinical progress on several cancers. However, most patients do not benefit from these therapies. Thus, many efforts are being made to identify new immune checkpoint receptor-ligand pathways t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Hyung-seung, Park, Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851444/
https://www.ncbi.nlm.nih.gov/pubmed/33298247
http://dx.doi.org/10.5483/BMBRep.2021.54.1.229